ATE365206T1 - Verfahren zur entwicklung von einem hiv impfstoff - Google Patents

Verfahren zur entwicklung von einem hiv impfstoff

Info

Publication number
ATE365206T1
ATE365206T1 AT99932507T AT99932507T ATE365206T1 AT E365206 T1 ATE365206 T1 AT E365206T1 AT 99932507 T AT99932507 T AT 99932507T AT 99932507 T AT99932507 T AT 99932507T AT E365206 T1 ATE365206 T1 AT E365206T1
Authority
AT
Austria
Prior art keywords
hiv
immune response
developing
hiv vaccine
inactivated
Prior art date
Application number
AT99932507T
Other languages
English (en)
Inventor
Adan Rios
Original Assignee
Adan Rios
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adan Rios filed Critical Adan Rios
Application granted granted Critical
Publication of ATE365206T1 publication Critical patent/ATE365206T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99932507T 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff ATE365206T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7464698P 1998-02-13 1998-02-13

Publications (1)

Publication Number Publication Date
ATE365206T1 true ATE365206T1 (de) 2007-07-15

Family

ID=22120781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932507T ATE365206T1 (de) 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff

Country Status (7)

Country Link
US (2) US6383806B1 (de)
EP (1) EP1056838B1 (de)
AT (1) ATE365206T1 (de)
AU (1) AU764938B2 (de)
CA (1) CA2323011C (de)
DE (1) DE69936337T2 (de)
WO (1) WO1999041360A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232494B1 (en) 1998-02-12 2001-05-15 Monsanto Company Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine
US6503753B1 (en) * 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
EP1363662A2 (de) * 2001-02-27 2003-11-26 Institut Pasteur Mhc-1-abhängige präsentation von hiv-1- virionantigenen ohne virale replikation: verwendung zur stimulierung von ctl und impfung in vivo
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
CA2557800A1 (en) * 2004-03-22 2005-10-06 Yossef Raviv Cellular and viral inactivation
KR100568542B1 (ko) * 2004-08-19 2006-04-07 삼성전자주식회사 자기 램 소자의 기록방법
ES2310848T3 (es) * 2004-10-04 2009-01-16 Biovaxim Limited Vacunas de virus enteros inactivados correspondientes a un subtipo para tratar pacientes con la infeccion vih.
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5912338A (en) 1990-10-12 1999-06-15 Benjamin Rovinski Nucleic acids encoding self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

Also Published As

Publication number Publication date
WO1999041360A1 (en) 1999-08-19
AU764938B2 (en) 2003-09-04
EP1056838A1 (de) 2000-12-06
DE69936337T2 (de) 2008-02-21
CA2323011C (en) 2013-01-15
DE69936337D1 (de) 2007-08-02
EP1056838B1 (de) 2007-06-20
US20030129200A1 (en) 2003-07-10
AU3293799A (en) 1999-08-30
CA2323011A1 (en) 1999-08-19
US6383806B1 (en) 2002-05-07
US6653130B2 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE69933433D1 (de) Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
ATE426412T1 (de) Adjuvante influenza-vakzine
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DK0534618T3 (da) Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
ZA805986B (en) Feline vaccines
CO5280138A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE278795T1 (de) Herpesviren für die modulation einer immunantwort
EP1439856A4 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
DE68920345D1 (de) Lebendes Kombinationsvakzin.
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
SE9202934D0 (sv) Vacciner mot melanom
WO2003054176A3 (en) Preparation of vaccines using photosensitizer and light
NZ510130A (en) Chicken anaemia viruses of low pathogenicity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties